The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Maintenance of Remission in ANCA-Associated Vasculitis

Maintenance of Remission in ANCA-Associated Vasculitis

September 5, 2012 • By Paul A. Monach, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A final area of great uncertainty is how maintenance therapy should be handled in patients receiving rituximab for induction of remission. Data presented at the 2010 ACR annual meeting but not yet published indicate that many patients treated with rituximab do suffer relapses, and that continuing rituximab treatment either on a scheduled basis (e.g., two 1,000-mg doses every six months) or after return of B cells and/or a rise in ANCA titer leads to low relapse rate.15,16 However, the optimal strategy for retreatment, including both the regimen and the choice of patients, has not been determined, and more importantly, no comparison to standard maintenance drugs, which are much less expensive and probably have lower risks of infection, has been made. A trial in progress in France (MAINRITSAN) compares rituximab to azathioprine for maintenance of remission.

You Might Also Like
  • ANCA-Associated Vasculitis in Systemic Sclerosis
  • Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash
  • Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash
Explore This Issue
September 2012
Also By This Author
  • The Latest on Eosinophilic Granulomatosis with Polyangiitis

What I Do…

For patients who receive cyclophosphamide for remission-induction, I follow the standard recommendation to switch to azathioprine or methotrexate between Months 3 and 6, continue maintenance to complete 18 months of treatment, then taper off the maintenance drug—in most patients. In the absence of data comparing 18-month to four-year strategies, I think the available data (e.g., see reference 9) suggest that the rate of first relapse accelerates or is unchanged after discontinuation of the maintenance drug at Month 18, rather than approaching a plateau as one would expect if patients with a tendency to relapse “declare themselves” early. Thus, for patients in whom a relapse might be devastating (e.g., due to tenuous renal function or poor tolerance of glucocorticoids), continuing maintenance therapy indefinitely is reasonable. It is also appropriate for patient preference to play a large role in decision making on this issue.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, I prefer to use rituximab for remission-induction therapy in most ANCA-positive patients, and particularly those who have previously received cyclophosphamide.4 Since there cannot yet be a strong guideline for maintenance therapy in this setting, I interpret the observational data as follows. For a patient with a first episode of AAV associated with anti-MPO antibodies, I do not use any subsequent maintenance drug (other than prednisone, see below). For a patient with a severe relapse, particularly if it occurs on a maintenance drug, I continue rituximab, either 1,000 mg every four months or 1,000 mg twice every six months indefinitely; however, since the community’s experience with such a strategy only extends for three to four years, I am sure that the prospect of discontinuing therapy will arise among patients who do well for several years. For a patient with a first episode of AAV associated with anti-PR3 antibodies, I usually recommend a second course of rituximab six months after the first, then watchful waiting. Although I do not routinely start azathioprine or methotrexate for maintenance four to 12 months after an initial course of rituximab, I expect that some colleagues do.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: ANCA vasculitis, drug, Glucocorticoids, granulomatosis with polyangiitis, Methotrexate, patient care, Research, rheumatologist, rituximab, VasculitisIssue: September 2012

You Might Also Like:
  • ANCA-Associated Vasculitis in Systemic Sclerosis
  • Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash
  • Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash
  • Malignancy Risk in ANCA-Associated Vasculitis Is Lower with Rituximab

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)